BioAdaptives, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioAdaptives, Inc. (OTC: BDPT) investigates, markets, and distributes natural plant, algal, and mushroom-based nutraceutical products and medical devices for humans and animals; core offerings include dietary supplements such as Zeranovia, a proprietary nutrient-optimizing ingredient for weight management and enhanced bioavailability in foods and beverages; Xcellara and PawPa for muscle and tissue repair, regeneration, and pet wellness; MyndMed, a nootropic for cognition, focus, memory, sleep improvement, and fatigue reduction; PluriPain, PrimiSleep, PrimiLungs, and PrimiCell for pain relief, sleep, lung health, and cellular wellness; Lung Flute, a respiratory medical device; equine products like Equine-in-One and uriP; and AI-driven FYO app for body composition analysis via smartphone photos. The company operates in the biotechnology and wellness sectors, targeting consumers, holistic healthcare practitioners, fitness professionals, sports teams, and pet owners with products addressing pain relief, immune support, antiviral activity, stress resistance, endurance, recovery, anti-aging, and weight control. Founded in 2013 and headquartered in Las Vegas, Nevada, BioAdaptives conducts human clinical trials and sources ingredients globally using proprietary enhancement techniques. In November 2024, the company announced a complete product overhaul, launching a redesigned lineup of next-generation nutraceuticals including enhanced weight management solutions that preserve muscle while targeting fat loss, advanced muscle repair, anti-aging formulations for humans, and Paw Partners pet products, incorporating customer feedback, rigorous testing, sustainability practices, and superior performance metrics. Recent developments encompass the January 2024 signing of a non-exclusive distributor agreement with Pixelcando S.L. in Spain for the FYO AI body composition app, enabling U.S. promotion to consumers, gyms, spas, and healthcare providers in a market projected to reach $2.6 billion by 2030; the October 2025 commercial launch of MyndMed following successful pilot tests with 2025 sales contracts doubling 2024 levels; plans for Zeranovia commercial introduction and revenue generation in 2025 after promising dosage trials showing significant weight loss with minimal side effects; late 2024 rollout of "Nu" branded enhanced practitioner products with upgraded ingredients and dosing; a robust acquisition pipeline for market expansion; and January 2025 FINRA approval of a common stock dividend payable on January 22.
BioAdaptives Launches MyndSystem™ Website — The First Supplement Platform Designed to Support Both Daytime Cognitive Performance and Overnight Brain Recovery
BioAdaptives, Inc. Launches MyndRenew™ to Complete the 24-Hour Brain Performance Cycle
BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing
BioAdaptives' MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety
BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience
BioAdaptives Announces National Launch of Pawpa™ Regen
BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements
Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial
BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors
BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors
This Wide Moat ETF Could Be 2025 Star
BioAdaptives, Inc. Launches Xcellara™ Stem Cell Activator – Harnessing Nature for Optimal Health
BioAdaptives, Inc.'s Board of Directors Approves a One-for-One Stock Dividend
BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia™
BioAdaptives, Inc. Announces 5 Unique Products Ready for Phased Entry Into the Nutritional Marketplace
BioAdaptives, Inc. Announces Complete Product Overhaul with New Line of Scientifically Advanced Solutions
BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split
BioAdaptives, Inc. Welcomes Gimhana Dissanayake to Its Board of Directors
BioAdaptives, Inc. Announces NaturaComplete™, an All-In-One Supplement to Optimize Its AI-Based FYO Obesity Management System
BioAdaptives Announces Low-Cost AI FYO Smartphone App Tracking System to Detect Unwanted Muscle Mass Loss Reported With Obesity Management